| Stereotactic ablative radiotherapy for the comprehensive treatment of 1–3 Oligometastatic tumors (SABR-COMET-3): study protocol for a randomized phase III trial R Olson, L Mathews, M Liu, D Schellenberg, B Mou, T Berrang, S Harrow, ... BMC cancer 20, 1-12, 2020 | 100 | 2020 |
| Treatment with stereotactic ablative radiotherapy for up to 5 oligometastases in patients with cancer: primary toxic effect results of the nonrandomized phase 2 SABR-5 clinical … R Olson, W Jiang, M Liu, A Bergman, D Schellenberg, B Mou, ... JAMA oncology 8 (11), 1644-1650, 2022 | 47 | 2022 |
| Progression-free survival and local control after SABR for up to 5 oligometastases: an analysis from the population-based phase 2 SABR-5 trial S Baker, W Jiang, B Mou, CR Lund, M Liu, AM Bergman, D Schellenberg, ... International Journal of Radiation Oncology* Biology* Physics 114 (4), 617-626, 2022 | 29 | 2022 |
| Long-term clinical outcomes and safety profile of SBRT for centrally located NSCLC ALH Arnett, B Mou, D Owen, SS Park, K Nelson, CL Hallemeier, T Sio, ... Advances in Radiation Oncology 4 (2), 422-428, 2019 | 29 | 2019 |
| Population-based phase II trial of stereotactic ablative radiotherapy (SABR) for up to 5 oligometastases: SABR-5 R Olson, M Liu, A Bergman, S Lam, F Hsu, B Mou, T Berrang, A Mestrovic, ... BMC cancer 18, 1-8, 2018 | 24 | 2018 |
| Stereotactic ablative radiotherapy for oligo-progressive cancers: results of the randomized phase II STOP trial D Schellenberg, Z Gabos, A Duimering, BJ Debenham, A Fairchild, ... International Journal of Radiation Oncology, Biology, Physics 117 (2), S58, 2023 | 16* | 2023 |
| Should organs at risk (OARs) be prioritized over target volume coverage in stereotactic ablative radiotherapy (SABR) for oligometastases? a secondary analysis of the population … RE Cereno, B Mou, S Baker, N Chng, G Arbour, A Bergman, M Liu, ... Radiotherapy and Oncology 182, 109576, 2023 | 15 | 2023 |
| Validation of the prognostic utility of ESTRO/EORTC oligometastatic disease classification: a secondary analysis from the population-based phase II SABR-5 trial S Baker, B Mou, W Jiang, M Liu, AM Bergman, D Schellenberg, ... International Journal of Radiation Oncology* Biology* Physics 114 (5), 849-855, 2022 | 14 | 2022 |
| Feasibility of proton transmission-beam stereotactic ablative radiotherapy versus photon stereotactic ablative radiotherapy for lung tumors: A dosimetric and feasibility study B Mou, CJ Beltran, SS Park, KR Olivier, KM Furutani Plos one 9 (6), e98621, 2014 | 14 | 2014 |
| Whole brain radiotherapy versus stereotactic radiosurgery in poor-prognosis patients with one to 10 brain metastases: a randomised feasibility study S Raman, B Mou, F Hsu, B Valev, A Cheung, I Vallières, R Ma, ... Clinical Oncology 32 (7), 442-451, 2020 | 13 | 2020 |
| Population based phase II trial of stereotactic ablative radiotherapy (SABR) for up to 5 oligometastases: preliminary results of the SABR-5 trial RA Olson, W Jiang, MC Liu, A Bergman, D Schellenberg, B Mou, ... International Journal of Radiation Oncology* Biology* Physics 111 (3), S4, 2021 | 12 | 2021 |
| SUPR-3D: A randomized phase iii trial comparing simple unplanned palliative radiotherapy versus 3d conformal radiotherapy for patients with bone metastases: study protocol R Olson, R Schlijper, N Chng, Q Matthews, M Arimare, L Mathews, F Hsu, ... BMC cancer 19, 1-8, 2019 | 12 | 2019 |
| Feasibility and full-course dosimetry of an intraoperatively placed multichannel brachytherapy catheter for accelerated partial breast irradiation BJ Stish, DH Pafundi, TJ Hieken, TJ Whitaker, KM Furutani, JW Jakub, ... Brachytherapy 15 (6), 796-803, 2016 | 8 | 2016 |
| Radiation oncology in a Canadian province: measures of workload and treatment complexity B Mou, AL Cooke, K Suderman Clinical Oncology 23 (1), 4-9, 2011 | 8 | 2011 |
| Challenges to improving access to stereotactic body radiation therapy and radiosurgery in the Philippines: A case study for lower-middle income countries EM Cruz-Lim, RE Cereno, JP Cañal, G Vega Jr, E Inocencio, B Mou International Journal of Radiation Oncology* Biology* Physics 116 (2), 430-438, 2023 | 7 | 2023 |
| Implementation of single-fraction lung stereotactic ablative radiotherapy in a multicenter provincial cancer program during the COVID-19 pandemic B Mou, D Hyde, C Araujo, L Bartha, A Bergman, M Liu, LR Bartha Cureus 13 (6), 2021 | 7 | 2021 |
| Stereotactic body radiotherapy for primary and metastatic liver tumors—the Mayo Clinic experience KW Merrell, JE Johnson, B Mou, BM Barney, KE Nelson, CS Mayo, ... Journal of Radiosurgery and SBRT 4 (2), 133, 2016 | 7 | 2016 |
| Upfront versus delayed systemic therapy in patients with oligometastatic cancer treated with SABR in the phase 2 SABR-5 trial S Baker, L Lechner, M Liu, JS Chang, EM Cruz-Lim, B Mou, W Jiang, ... International Journal of Radiation Oncology* Biology* Physics 118 (5), 1497-1506, 2024 | 5 | 2024 |
| Predictors of early polymetastatic relapse after SABR for up to 5 oligometastases: A secondary analysis of the phase II SABR-5 trial S Baker, B Mou, W Jiang, M Liu, AM Bergman, D Schellenberg, ... International Journal of Radiation Oncology* Biology* Physics 114 (5), 856-861, 2022 | 5 | 2022 |
| Prospective Longitudinal Assessment of quality of life after stereotactic ablative radiotherapy for oligometastases: Analysis of the population-based SABR-5 phase II trial EM Cruz-Lim, B Mou, S Baker, G Arbour, K Stefanyk, W Jiang, M Liu, ... Clinical Oncology 36 (3), 148-156, 2024 | 4 | 2024 |
